Exclusive Summary

• Patent expiry opens the market, while global scarcity creates market acquisition opportunities for high-quality generics.
• Essential for critical conditions, listed in WHO EML and guideline-recommended, ensuring stable and significant market demand.
• In-house API production and bioequivalence approval provide strong competitive advantages in quality and cost.
• Classified as an essential and shortage-prone drug in China, highlighting its critical clinical value and market niche.
• Significant global unmet need for cost-effective, high-quality emergency and critical care medications.

Asset Materials

Contact Us for Full Materials